Artiva Biotherapeutics pushes AlloNK cell therapy toward Phase 3 for tough-to-treat rheumatoid arthritis

Artiva Biotherapeutics is stepping up its push in autoimmune cell therapy. The company will present new data on its AlloNK program at ACR Convergence 2026. This isn’t just an update. Artiva is getting ready to move AlloNK, its off-the-shelf natural killer (NK) cell therapy, into a Phase 3 trial for patients with refractory rheumatoid arthritis (RA) later this year.

Artiva plans one oral and two poster presentations at the American College of Rheumatology’s annual meeting in Orlando. A live webcast is set for November 9, 2026. The webcast will break down updated clinical results from at least 20 patients with refractory RA, each followed for at least six months. It will also focus on a group of at least 10 patients who meet the main criteria for the planned Phase 3 trial. According to a BioPharm International report, the Phase 3 trial will enroll about 150 patients. The main goal is to reach ACR50 at six months.

AlloNK clinical evidence and safety profile

One highlight: Artiva will present an oral abstract showing that outpatient, non-genetically modified NK cells plus rituximab led to responses in 34 patients with rheumatologic diseases. The company says these results are on par with autologous CAR T therapy. The industry analysis details that this Phase 2a basket trial included patients with refractory RA, Sjögren disease, and systemic sclerosis. All had at least six months of follow-up.

Another poster will show safety data from a larger group of 60 patients. The focus is on a strong tolerability profile and steady, deep B-cell depletion. That’s a key goal in B-cell-driven autoimmune diseases.

A third poster will look at a tough problem: a registry analysis of U.S. patients with RA who have failed two or more types of biologic or targeted synthetic DMARDs. The data show high unmet need and low response rates in this group.

Therapeutic strategy and broader pipeline

AlloNK (also called AB-101) is an allogeneic, cryopreserved NK cell therapy. It’s built to boost antibody-dependent cell killing when used with drugs like rituximab. The treatment is meant for outpatient use. The goal is to make deep B-cell depletion possible in community rheumatology clinics. BioPharm International notes that AlloNK is not genetically modified. That sets it apart from autologous CAR T therapies and supports its off-the-shelf, ready-to-use approach.

Artiva is also testing AlloNK in Sjögren disease, systemic sclerosis, and myositis. The company’s method is different from the more complex, resource-heavy autologous CAR T therapies. That difference has caught attention in the cell therapy world. For comparison, reported earlier results from Immix Biopharma’s NXC-201 CAR-T program in AL amyloidosis show the promise of cell therapies in tough immune diseases. But they also highlight the logistical and safety hurdles of autologous approaches.

Next steps and industry implications

Artiva plans to start its Phase 3 trial for AlloNK in refractory RA in the second half of 2026. The company is betting that its platform can deliver both strong results and outpatient convenience. The webcast will feature a live Q&A and a replay for 90 days. Artiva wants to keep investors and the clinical community in the loop.

Moving AlloNK into late-stage testing is a big test for allogeneic NK cell therapies in autoimmune disease. If the Phase 3 trial backs up the early signs of efficacy and safety, the field could shift toward more accessible, scalable cell therapies for patients who have run out of standard options. For now, the data are still early. Artiva’s strategy is a clear bet that outpatient, off-the-shelf NK cell regimens can find a real place in autoimmune care.